Scarica l'app Stockscreener
23.96
3.33%
0.785
Precedente Chiudi:
$23.18
Aprire:
$23.52
Volume 24 ore:
923.74K
Relative Volume:
0.16
Capitalizzazione di mercato:
$11.97B
Reddito:
$4.89B
Utile/perdita netta:
$-242.00M
Rapporto P/E:
-49.01
EPS:
-0.489
Flusso di cassa netto:
$315.00M
1 W Prestazione:
+2.40%
1M Prestazione:
+10.23%
6M Prestazione:
+7.02%
1 anno Prestazione:
+77.29%
Intervallo 1D:
$23.50
$24.18
Intervallo di 1 settimana:
$23.07
$24.54
Portata 52W:
$13.39
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.96 | 11.58B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
15.74 | 50.05B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.215 | 39.45B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.53 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.37 | 32.21B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.50 | 23.11B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Citigroup | Buy |
| 2026-01-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-21 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2025-11-19 | Aggiornamento | Argus | Hold → Buy |
| 2025-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis - TradingKey
A Look at Elanco Animal Health Inc (ELAN) After 3.0% Decline -- GF Value $15.57 vs Price $23.18 - GuruFocus
Credelio from Elanco Animal Health Inc.soft chew once a month against ticks and fleas - AD HOC NEWS
Pet Healthcare Spending Is Soaring. These Stocks Are Positioned to Clean Up - AOL.com
Elanco Animal Health Inc (ELAN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elanco To Launch $25 Million Corporate Venture Capital Platform - Pulse 2.0
Neurizon, Elanco Ink Long-Term Supply Agreement for Human Health Monepantel - Contract Pharma
T. Rowe Price Investment Management Inc. Increases Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ELAN Maintained by TD Cowen -- Price Target Raised to $32 - GuruFocus
ELANElanco Animal Health Inc Stock Price and Quote - Finviz
Elanco to launch $25M VC program focused on animal health innovation - Inside INdiana Business
Elanco Ventures Expands Animal Health Innovation Ecosystem - Kalkine Media
Elanco (ELAN) Launches Venture Capital Platform for Animal Healt - GuruFocus
Veterinary API Manufacturing Market to Reach USD 18.48 Billion by 2035 as Animal Health Investments and Zoonotic Disease Prevention Accelerate – SNS Insider - GlobeNewswire Inc.
TD Cowen Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
Elanco Animal Health Is Maintained at Buy by TD Cowen - Moomoo
TD Cowen raises Elanco Animal Health price target on product launches - Investing.com Canada
Elanco Animal Health Incorporated Establishes Elanco Ventures Corporate Venture Capital Platform - marketscreener.com
Elanco plans VC platform to fast track animal health innovation - Feedstuffs
Elanco Animal Health Launches Venture Capital Platform - Intellectia AI
Elanco launches $25 million venture capital fund for animal health By Investing.com - Investing.com Canada
Elanco bets $25 million on startup tech for animal health - Stock Titan
Elanco Animal Health Inc (ELAN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elanco Animal Health (ELAN) PT Raised to $32 at TD Cowen; Names Best Smidcap Idea - StreetInsider
Elanco Animal Health Inc (ELAN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elanco Animal Health Inc (ELAN) Institutional Confidence - TradingKey
Elanco Animal Health Inc (ELAN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elanco Animal Health Inc (ELAN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Elanco Animal Health Inc (ELAN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elanco Animal Health Inc (ELAN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Look at Elanco Animal Health Inc (ELAN) After 3.5% Decline -- GF Value $15.55 vs Price $23.39 - GuruFocus
ExodusPoint Capital Management LP Buys 491,617 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) CFO VanHimbergen receives deferred stock unit grant under deferral plan - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives deferred stock unit grant - Stock Titan
Deferred stock award to Elanco (NYSE: ELAN) executive disclosed - Stock Titan
Elanco CEO: Screwworm Easier To Manage Than Contain - marketscreener.com
Elanco Announces USDA Approval of TruCan Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - Investing News Network
Elanco (ELAN) Introduces TruCan Ultra Lyme-L4 Vaccine for Dogs - GuruFocus
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the Fir - GuruFocus
9 New 4-Star Stocks This Week - Morningstar
Elanco receives USDA approval for canine combination vaccine By Investing.com - Investing.com Canada
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs - PR Newswire
New low-volume dog vaccine targets Lyme and leptospirosis in a single shot - Stock Titan
Elanco Animal Health Incorporated $ELAN Position Reduced by Black Creek Investment Management Inc. - MarketBeat
Private Management Group Inc. Reduces Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Barclays Reaffirms Their Buy Rating on Elanco Animal Health (ELAN) - The Globe and Mail
Elanco Animal Health Q1 earnings call highlights - MSN
Brandes Investment Partners LP Has $95.09 Million Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Shares Surge 3.5% -- What GF Sco - GuruFocus
Norges Bank Makes New $32.42 Million Investment in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):